Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)Young Kwang Chae, Francis J. Giles, Ayush Arya et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 468
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyApar Kishor Ganti, Miranda Hughes, Billy W. Loo et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 459
Immunotherapeutic approaches for small-cell lung cancerWade T. Iams, Leora Horn, Jason Porter|Nature Reviews Clinical Oncology|2020Cited by 346
Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)Young Kwang Chae, Marcelo Cruz, Sangmin Chang et al.|Scientific Reports|2018Cited by 258
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway BlockadeWade T. Iams, Christine M. Lovly|Clinical Cancer Research|2015Cited by 178